223 related articles for article (PubMed ID: 10052976)
1. 3-(Piperazinylpropyl)indoles: selective, orally bioavailable h5-HT1D receptor agonists as potential antimigraine agents.
Chambers MS; Street LJ; Goodacre S; Hobbs SC; Hunt P; Jelley RA; Matassa VG; Reeve AJ; Sternfeld F; Beer MS; Stanton JA; Rathbone D; Watt AP; MacLeod AM
J Med Chem; 1999 Feb; 42(4):691-705. PubMed ID: 10052976
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and serotonergic activity of 3-[2-(pyrrolidin-1-yl)ethyl]indoles: potent agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B receptor.
Sternfeld F; Guiblin AR; Jelley RA; Matassa VG; Reeve AJ; Hunt PA; Beer MS; Heald A; Stanton JA; Sohal B; Watt AP; Street LJ
J Med Chem; 1999 Feb; 42(4):677-90. PubMed ID: 10052975
[TBL] [Abstract][Full Text] [Related]
3. Benzylimidazolines as h5-HT1B/1D serotonin receptor ligands: a structure-affinity investigation.
Law H; Dukat M; Teitler M; Lee DK; Mazzocco L; Kamboj R; Rampersad V; Prisinzano T; Glennon RA
J Med Chem; 1998 Jun; 41(13):2243-51. PubMed ID: 9632357
[TBL] [Abstract][Full Text] [Related]
4. The selective 5-HT1B receptor inverse agonist 1'-methyl-5-[[2'-methyl-4'-(5-methyl-1,2, 4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro- spiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo.
Gaster LM; Blaney FE; Davies S; Duckworth DM; Ham P; Jenkins S; Jennings AJ; Joiner GF; King FD; Mulholland KR; Wyman PA; Hagan JJ; Hatcher J; Jones BJ; Middlemiss DN; Price GW; Riley G; Roberts C; Routledge C; Selkirk J; Slade PD
J Med Chem; 1998 Apr; 41(8):1218-35. PubMed ID: 9548813
[TBL] [Abstract][Full Text] [Related]
5. 3-[2-(Pyrrolidin-1-yl)ethyl]indoles and 3-[3-(piperidin-1-yl)propyl]indoles: agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B subtype.
Castro JL; Street LJ; Guiblin AR; Jelley RA; Russell MG; Sternfeld F; Beer MS; Stanton JA; Matassa VG
J Med Chem; 1997 Oct; 40(22):3497-500. PubMed ID: 9357514
[No Abstract] [Full Text] [Related]
6. Fluorination of 3-(3-(piperidin-1-yl)propyl)indoles and 3-(3-(piperazin-1-yl)propyl)indoles gives selective human 5-HT1D receptor ligands with improved pharmacokinetic profiles.
van Niel MB; Collins I; Beer MS; Broughton HB; Cheng SK; Goodacre SC; Heald A; Locker KL; MacLeod AM; Morrison D; Moyes CR; O'Connor D; Pike A; Rowley M; Russell MG; Sohal B; Stanton JA; Thomas S; Verrier H; Watt AP; Castro JL
J Med Chem; 1999 Jun; 42(12):2087-104. PubMed ID: 10377215
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of oral absorption in selective 5-HT1D receptor agonists: fluorinated 3-[3-(piperidin-1-yl)propyl]indoles.
Castro JL; Collins I; Russell MG; Watt AP; Sohal B; Rathbone D; Beer MS; Stanton JA
J Med Chem; 1998 Jul; 41(15):2667-70. PubMed ID: 9667955
[No Abstract] [Full Text] [Related]
8. Designing selective, high affinity ligands of 5-HT1D receptor by covalent dimerization of 5-HT1F ligands derived from 4-fluoro-N-[3-(1-methyl-4-piperidinyl)-1H-indol-5-yl]benzamide.
Choi SK; Green D; Ho A; Klein U; Marquess D; Taylor R; Turner SD
J Med Chem; 2008 Jun; 51(12):3609-16. PubMed ID: 18507369
[TBL] [Abstract][Full Text] [Related]
9. Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan.
Leysen JE; Gommeren W; Heylen L; Luyten WH; Van de Weyer I; Vanhoenacker P; Haegeman G; Schotte A; Van Gompel P; Wouters R; Lesage AS
Mol Pharmacol; 1996 Dec; 50(6):1567-80. PubMed ID: 8967979
[TBL] [Abstract][Full Text] [Related]
10. SB-224289--a novel selective (human) 5-HT1B receptor antagonist with negative intrinsic activity.
Selkirk JV; Scott C; Ho M; Burton MJ; Watson J; Gaster LM; Collin L; Jones BJ; Middlemiss DN; Price GW
Br J Pharmacol; 1998 Sep; 125(1):202-8. PubMed ID: 9776361
[TBL] [Abstract][Full Text] [Related]
11. 2-(1-Naphthyloxy)ethylamines with enhanced affinity for human 5-HT1D beta (h5-HT1B) serotonin receptors.
Ismaiel AM; Dukat M; Law H; Kamboj R; Fan E; Lee DK; Mazzocco L; Buekschkens D; Teitler M; Pierson ME; Glennon RA
J Med Chem; 1997 Dec; 40(26):4415-9. PubMed ID: 9435911
[TBL] [Abstract][Full Text] [Related]
12. 5-HT1B receptor antagonist properties of novel arylpiperazide derivatives of 1-naphthylpiperazine.
Jorand-Lebrun C; Pauwels PJ; Palmier C; Moret C; Chopin P; Perez M; Marien M; Halazy S
J Med Chem; 1997 Nov; 40(24):3974-8. PubMed ID: 9397179
[TBL] [Abstract][Full Text] [Related]
13. Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines.
Lesage AS; Wouters R; Van Gompel P; Heylen L; Vanhoenacker P; Haegeman G; Luyten WH; Leysen JE
Br J Pharmacol; 1998 Apr; 123(8):1655-65. PubMed ID: 9605573
[TBL] [Abstract][Full Text] [Related]
14. F 11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5-HT1B/1D receptors in models relevant to migraine.
John GW; Pauwels PJ; Perez M; Halazy S; Le Grand B; Verscheure Y; Valentin JP; Palmier C; Wurch T; Chopin P; Marien M; Kleven MS; Koek W; Assie MB; Carilla-Durand E; Tarayre JP; Colpaert FC
J Pharmacol Exp Ther; 1999 Jul; 290(1):83-95. PubMed ID: 10381763
[TBL] [Abstract][Full Text] [Related]
15. 3-[3-(Piperidin-1-yl)propyl]indoles as highly selective h5-HT(1D) receptor agonists.
Russell MG; Matassa VG; Pengilley RR; van Niel MB; Sohal B; Watt AP; Hitzel L; Beer MS; Stanton JA; Broughton HB; Castro JL
J Med Chem; 1999 Dec; 42(24):4981-5001. PubMed ID: 10585208
[TBL] [Abstract][Full Text] [Related]
16. Selective, orally active 5-HT1D receptor agonists as potential antimigraine agents.
MacLeod AM; Street LJ; Reeve AJ; Jelley RA; Sternfeld F; Beer MS; Stanton JA; Watt AP; Rathbone D; Matassa VG
J Med Chem; 1997 Oct; 40(22):3501-3. PubMed ID: 9357515
[No Abstract] [Full Text] [Related]
17. 8-Piperazinyl-2,3-dihydropyrrolo[3,2-g]isoquinolines: potent, selective, orally bioavailable 5-HT1 receptor ligands.
Heightman TD; Gaster LM; Pardoe SL; Pilleux JP; Hadley MS; Middlemiss DN; Price GW; Roberts C; Scott CM; Watson JM; Gordon LJ; Holland VA; Powles J; Riley GJ; Stean TO; Trail BK; Upton N; Austin NE; Ayrton AD; Coleman T; Cutler L
Bioorg Med Chem Lett; 2005 Oct; 15(19):4370-4. PubMed ID: 16039851
[TBL] [Abstract][Full Text] [Related]
18. Binding of O-alkyl derivatives of serotonin at human 5-HT1D beta receptors.
Glennon RA; Hong SS; Bondarev M; Law H; Dukat M; Rakhi S; Power P; Fan E; Kinneau D; Kamboj R; Teitler M; Herrick-Davis K; Smith C
J Med Chem; 1996 Jan; 39(1):314-22. PubMed ID: 8568822
[TBL] [Abstract][Full Text] [Related]
19. 4-Hydroxy-1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperidines: selective h5-HT1D agonists for the treatment of migraine.
Bourrain S; Neduvelil JG; Beer MS; Stanton JA; Showell GA; MacLeod AM
Bioorg Med Chem Lett; 1999 Dec; 9(23):3369-74. PubMed ID: 10612601
[TBL] [Abstract][Full Text] [Related]
20. SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors.
Price GW; Burton MJ; Collin LJ; Duckworth M; Gaster L; Göthert M; Jones BJ; Roberts C; Watson JM; Middlemiss DN
Naunyn Schmiedebergs Arch Pharmacol; 1997 Sep; 356(3):312-20. PubMed ID: 9303567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]